This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Drug Safety and Risk Management Advisory Committee | |
|---|---|
| Name | Drug Safety and Risk Management Advisory Committee |
| Formation | 2005 |
| Type | Advisory committee |
| Leader title | Chair |
| Parent organization | Food and Drug Administration |
| Headquarters | Silver Spring, Maryland |
Drug Safety and Risk Management Advisory Committee is an expert advisory body constituted to provide independent scientific advice on pharmaceutical safety, risk communication, and postmarketing surveillance to the Food and Drug Administration and other federal entities. The committee convenes clinicians, epidemiologists, pharmacologists, statisticians, and patient representatives to evaluate safety signals, risk mitigation strategies, and labeling changes for marketed therapeutics. Its recommendations have informed decisions involving high-profile products and intersect with regulatory frameworks such as the Food, Drug, and Cosmetic Act and programs at the Centers for Disease Control and Prevention.
The committee functions as a specialized panel within the regulatory advisory system alongside bodies such as the Vaccines and Related Biological Products Advisory Committee and the Oncologic Drugs Advisory Committee, offering expert assessment of adverse event data from sources like the Vaccine Adverse Event Reporting System, Sentinel System, and pharmacoepidemiologic studies. Members bring experience from institutions including Johns Hopkins University, Harvard Medical School, Mayo Clinic, University of California, San Francisco, and Columbia University. The group interfaces with stakeholders such as the Pharmaceutical Research and Manufacturers of America, patient advocacy organizations like National Patient Safety Foundation affiliates, and international regulators including the European Medicines Agency and the World Health Organization.
The advisory body was established amid heightened attention to postmarketing safety after high-profile actions involving products reviewed by the Advisory Committee on Cardiovascular Devices and incidents connected to litigation involving companies such as Merck & Co., GlaxoSmithKline, and Pfizer. Its creation followed legislative and policy developments influenced by cases like the withdrawal of Vioxx and safety reviews of Avandia, and reflects reforms debated in hearings before the United States Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce. The committee’s charter and scope were shaped by input from advisory mechanisms established under administrations including those of George W. Bush and Barack Obama.
Membership criteria emphasize expertise drawn from academic centers such as Stanford University School of Medicine, Yale School of Medicine, University of Pennsylvania, and University of Michigan Medical School. Chairs have included clinicians and scientists affiliated with institutions like University of Washington and Duke University School of Medicine. Organizational relationships link the committee to the Center for Drug Evaluation and Research, the Office of Surveillance and Epidemiology, and interagency partners such as the National Institutes of Health and the Agency for Healthcare Research and Quality. Appointments are announced by the Food and Drug Administration Commissioner and involve clearance processes influenced by the Federal Advisory Committee Act.
The committee evaluates risk–benefit profiles, advises on Risk Evaluation and Mitigation Strategies (REMS), and reviews postmarketing study designs, drawing on evidence from randomized trials at centers like Cleveland Clinic and observational cohorts modeled at Kaiser Permanente. It provides recommendations on safety labeling changes, boxed warnings, and communication strategies directed to stakeholders including the American Medical Association, American Pharmacists Association, and specialty societies such as the American College of Cardiology and American Academy of Pediatrics. The committee examines pharmacovigilance data from registries, clinical trial databases maintained by entities like ClinicalTrials.gov, and international signal detection from the International Council for Harmonisation.
Meetings are announced in the Federal Register and follow procedures consistent with the Freedom of Information Act and transparency norms observed by panels such as the Presidential Advisory Committee on Gulf War Veterans' Illnesses. Agendas include presentations from FDA staff, external experts from universities and industry such as Novartis and Johnson & Johnson, and public testimony by patient advocates from groups like American Heart Association and American Diabetes Association. Decisions are advisory; votes are recorded and minority views documented, paralleling practices used by the Advisory Committee on Immunization Practices. Conflict-of-interest rules reference standards applied by the Office of Government Ethics.
The committee has issued influential recommendations on REMS for opioid analgesics, safety labeling for antidepressants in youth reviewed alongside American Academy of Child and Adolescent Psychiatry concerns, and risk management for anticoagulants scrutinized by societies like the International Society on Thrombosis and Haemostasis. Its advice contributed to regulatory actions affecting products from manufacturers including Eli Lilly and Company, AstraZeneca, and Bristol-Myers Squibb, and informed international guidance adopted by the European Commission in pharmacovigilance policy. Outcomes have included mandated postmarketing studies, boxed warnings, restricted distribution programs, and revised informed consent templates used in multicenter trials at institutions such as Massachusetts General Hospital.
Critics have cited perceived conflicts of interest when panelists had links to industry firms such as AbbVie or consultancies serving pharmaceutical clients, echoing debates involving the National Academies of Sciences, Engineering, and Medicine. Concerns have also focused on transparency of underlying data from sponsor-submitted trials conducted by contract research organizations like Quintiles (now IQVIA) and on the balance between rapid access advocated by patient groups such as PatientsLikeMe and conservative risk mitigation recommended by academic societies. Legal challenges and media scrutiny following high-profile decisions have invoked actors such as the Consumer Federation of America and coverage in outlets including The New York Times and The Washington Post.
Category:Advisory committees of the United States federal government